Tolerance and safety of nifurtimox in patients with chronic Chagas disease

Clinical Infectious Diseases

Volumn 51, Issue 10, 2010, Pages

  Jackson, Yves ^a   Alirol, Emilie ^a   Getaz, Laurent ^a   Wolff, Hans ^a   Combescure, Christophe ^a   Chappuis, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NIFURTIMOX;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHAGAS DISEASE; CHRONIC DISEASE; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; EOSINOPHILIA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MYALGIA; MYOCARDITIS; NAUSEA; NEUROPATHY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SWITZERLAND; TREATMENT DURATION; TRYPANOSOMA CRUZI; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; CHAGAS DISEASE; CHRONIC DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LATIN AMERICA; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIFURTIMOX; SWITZERLAND; TRYPANOCIDAL AGENTS;

EID: 78349302742     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656917     Document Type: Article

References (26)

1. Organisacion Panamericana de la Salud. Estimacion cuantitativa de la enfermedad de Chagas en las Américas. Montevideo, Uruguay: World Health Organization, 2006.
2. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007; 102(1):75-85.
3. Munoz J, Gomez I, Prat J, Gallego M, et al. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop 2009; 111(1):51-55.
4. Rassi A Jr, Rassi A, Marin-Neto JM. Chagas disease. Lancet 2010; 375: 1388-1402.
5. Control of Chagas disease. World Health Organ Tech Rep Ser 2002; 905:1-109.
6. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; 40(1):1-10.
7. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144(10):724-734. (Pubitemid 46780632)
8. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009; 95(7):524-534.
9. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma cruzi - specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49(11):1675-1684.
10. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007; 298(18):2171-2181. (Pubitemid 350106656)
11. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non inferiority trial. Lancet 2009; 374(9683):56-64.
12. Coura JR. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 2009; 104(4):549-554.
13. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115(1-2):55-68.
14. Coura JR, de Abreu LL,Willcox HP, PetanaW. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 1997; 30(2): 139-144.
15. Jackson Y, Getaz L, Wolff H, et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 2010; 4(2):e592.
16. Levi GC, Lobo IM, Kallas EG, Amato Neto V. Etiological drug treatment of human infection by Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1996; 38(1):35-38. (Pubitemid 26151801)
17. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006; 25(8):471-479.
18. Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H. Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop 2005; 38(2):41-45.
19. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7(2):157-163.
20. Levi GC, Amata Neto V, Sant'anna IF. Side-effects of Ro 7-1051, a nitroimidazole used tentatively as a specific treatment for Chagas' disease. Rev Inst Med Trop Sao Paulo 1975; 17:49-54.
21. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003; 206(4):353-356. (Pubitemid 36677029)
22. Rassi A, Amato Neto V, de Siqueira AF, et al. Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid. Rev Soc Bras Med Trop 2002; 35(6):547-550. (Pubitemid 36313979)
23. Wolff H, Besson M, Holst M, Induni E, Stalder H. Social inequalities and health: experiences of a mobile health care unit in Geneva. Rev Med Suisse 2005; 1(34):2218-2222. (Pubitemid 44503421)
24. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 2009; 3(7):e488.
25. Moloney A. Trial renews interest in Chagas' disease. Lancet 2009; 374(9700):1490.
26. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3(7):e484.